← back to search

Pierre Baumann

Zero to Three · CH
Area of research
Pharmacology · Pediatrics, Perinatology and Child Health
Research interest
Research interests include Treatment of Major Depression, Pharmacogenetics and Drug Metabolism, Schizophrenia research and treatment, and Pharmaceutical studies and practices.
h-index
63
citations
15,341
works
1,015
NIH funding
primary concept
email

Recent publications

Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis.
2025cited by 14position: contributordoi
How to Determine a Therapeutic Reference Range for a Psychotropic Drug Systematically? Recommendations of the TDM Task Force of the AGNP
Therapeutic Drug Monitoring 2025cited by 6position: middledoi
How to Determine a Therapeutic Reference Range for a Psychotropic Drug Systematically? Recommendations of the TDM Task Force of the AGNP.
2025cited by 3position: contributordoi
Behind the Curtain: Therapeutic Drug Monitoring of Psychotropic Drugs from a Laboratory Analytical Perspective.
2024cited by 7position: contributordoi
Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative review.
2023cited by 4position: contributordoi
Citalopram <i>in vitro</i> metabolism in a Beagle dog: A role for CYP2D15 in the production of toxic didesmethylcitalopram?
2023cited by 2position: contributordoi
Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants
The World Journal of Biological Psychiatry 2021cited by 39position: middledoi
Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants.
2021cited by 28position: contributordoi
Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs.
2021cited by 19position: contributordoi
Plasma Concentrations and Cardiovascular Effects of Citalopram Enantiomers After Oral Versus Infusion Citalopram Therapy in Dextromethorphan-Mephenytoin-Phenotyped Patients With Major Depression.
2021cited by 1position: contributordoi
Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice
The Journal of Clinical Psychiatry 2020cited by 141position: middledoi
Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie.
2020cited by 79position: contributordoi
Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs
Therapeutic Drug Monitoring 2020cited by 49position: middledoi
The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients.
2020cited by 1position: contributordoi
[Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP].
2019cited by 3position: contributordoi
About the Misleading Use of Stereodescriptors in Labeling the Stereoisomers of Milnacipran and Levomilnacipran.
2019cited by 0position: contributordoi
Clinical Psychopharmacology in Switzerland.
2019cited by 0position: contributordoi
[Erratum to: Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP].
2019cited by 0position: contributordoi
Erratum zu: Therapeutisches Drug-Monitoring in der Neuropsychopharmakologie
Der Nervenarzt 2019cited by 0position: middledoi
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Pharmacopsychiatry 2018cited by 321position: lastdoi
TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians
The World Journal of Biological Psychiatry 2018cited by 144position: middledoi
Therapeutisches Drug-Monitoring in der Neuropsychopharmakologie
Der Nervenarzt 2018cited by 16position: middledoi
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Pharmacopsychiatry 2017cited by 1,389position: lastdoi
A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression
Journal of Affective Disorders 2014cited by 135position: middledoi
Therapeutisches Drug-Monitoring in der Psychiatrie
Der Nervenarzt 2013cited by 34position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Christoph Hiemke · University of Applied Sciences Mainz9 papers (2013–2025)Gerhard Gründer · Johannes Gutenberg University Mainz4 papers (2013–2025)Gerald Zernig · Johannes Gutenberg University Mainz4 papers (2013–2025) · 3 papers (2020–2023)Andreas Conca · Northwell Health3 papers (2013–2020)Georgios Schoretsanitis · Northwell Health3 papers (2020–2025)Julia Stingl · University of Bonn3 papers (2019–2021)John M. Kane · North Shore Diabetes and Endocrine Associates2 papers (2020–2020)Xenia M. Hart · University Hospital Heidelberg2 papers (2020–2025)Werner Steimer · Technical University of Munich2 papers (2020–2025) · 2 papers (2020–2020) · 2 papers (2020–2025) · 1 papers (2013–2013)Donald Goff · New York University1 papers (2020–2020)Rainald Mößner · University of Tübingen1 papers (2020–2020)Henricus G. Ruhé · Radboud University Medical Center1 papers (2021–2021)Josef Priller · University of Sheffield1 papers (2025–2025)Gerhard Gründer · Heidelberg University1 papers (2021–2021)Maxim Kuzin · Arbeitsgruppe „Therapeutisches Drug Monitoring“ der AGNP1 papers (2023–2023)Edoardo Spina · University of Messina1 papers (2021–2021)